X

Bis zu 814 Euro pro Jahr: Gebühren oder Rendite? Du entscheidest.

Laut Stiftung Warentest (12/2025) zahlst du beim 'Kostensieger' finanzen.net ZERO jährlich bis zu 814 Euro weniger Gebühren als bei anderen Anbietern. Wechsle jetzt zum Broker von finanzen.net und spare bei jedem Trade!

Depot eröffnen Mehr zum Test

Nicht mehr anzeigen

Q32 Bio Aktie

Kaufen

Verkaufen

Q32 Bio Aktien-Sparplan Q32 Bio Aktien-Sparplan

5,00 EUR +0,72 EUR +16,82 %

19:03:35

STU

5,90 USD +0,75 USD +14,56 %

19:04:18

BTT

Q32 Bio jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Smartphone

Marktkap.56,23 Mio. EUR

Div. Rendite0,00%

WKNA4ZZ0Z

ISINUS7469641051

SymbolQTTB

Q32 Bio Aktien News

Sortieren:Datum Meistgelesen

01.12.25PR NewswireQ32 Bio Sells Complement Inhibitor ADX-097

13.11.25PR NewswireQ32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

21.10.25PR NewswireQ32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

WerbungQ32 Bio-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

28.08.25PR NewswireQ32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference

06.08.25PR NewswireQ32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

25.06.25PR NewswireQ32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

08.05.25PR NewswireQ32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

30.04.25PR NewswireQ32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

16.04.25PR NewswireQ32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

11.03.25PR NewswireQ32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

08.03.25PR NewswireQ32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

28.02.25PR NewswireQ32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

26.02.25PR NewswireQ32 Bio to Participate in Upcoming March Investor Conferences

10.02.25PR NewswireQ32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

04.02.25PR NewswireQ32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

10.12.24PR NewswireQ32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

07.11.24PR NewswireQ32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

05.11.24PR NewswireQ32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

14.10.24PR NewswireQ32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

29.08.24PR NewswireQ32 Bio to Participate in Upcoming September Investor Conferences

09.07.24PR NewswireQ32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

01.07.24PR NewswireQ32 Bio Joins Russell 3000® Index

09.05.24PR NewswireQ32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

03.04.24PR NewswireQ32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

Q32 Bio News

Q32 Bio News: auf dieser Seite finden Sie alle Q32 Bio News und Nachrichten zur Q32 Bio Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Q32 Bio News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Q32 Bio News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.